serdemetan

{
  "id": "MLC-T-ONC-016688",
  "term": "serdemetan",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, small-molecule HDM2 antagonist with potential antineoplastic activity. Serdemetan inhibits the binding of the HDM2-p53 complex to the proteasome, blocking the degradation of p53; p53 signaling and p53-mediated induction of tumor cell apoptosis may thus be restored. In addition to p53, degradation of other HDM2 client proteins may be inhibited. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, this oncoprotein has been implicated in cancer cell proliferation and survival.",
  "synonyms": [
    "HDM2 antagonist JNJ-26854165"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/serdemetan/"
}